Literature DB >> 35764603

Molecular characteristics, immune evasion, and impact of SARS-CoV-2 variants.

Cong Sun1, Chu Xie1, Guo-Long Bu1, Lan-Yi Zhong1, Mu-Sheng Zeng2,3.   

Abstract

The persistent COVID-19 pandemic since 2020 has brought an enormous public health burden to the global society and is accompanied by various evolution of the virus genome. The consistently emerging SARS-CoV-2 variants harboring critical mutations impact the molecular characteristics of viral proteins and display heterogeneous behaviors in immune evasion, transmissibility, and the clinical manifestation during infection, which differ each strain and endow them with distinguished features during populational spread. Several SARS-CoV-2 variants, identified as Variants of Concern (VOC) by the World Health Organization, challenged global efforts on COVID-19 control due to the rapid worldwide spread and enhanced immune evasion from current antibodies and vaccines. Moreover, the recent Omicron variant even exacerbated the global anxiety in the continuous pandemic. Its significant evasion from current medical treatment and disease control even highlights the necessity of combinatory investigation of the mutational pattern and influence of the mutations on viral dynamics against populational immunity, which would greatly facilitate drug and vaccine development and benefit the global public health policymaking. Hence in this review, we summarized the molecular characteristics, immune evasion, and impacts of the SARS-CoV-2 variants and focused on the parallel comparison of different variants in mutational profile, transmissibility and tropism alteration, treatment effectiveness, and clinical manifestations, in order to provide a comprehensive landscape for SARS-CoV-2 variant research.
© 2022. The Author(s).

Entities:  

Mesh:

Year:  2022        PMID: 35764603      PMCID: PMC9240077          DOI: 10.1038/s41392-022-01039-2

Source DB:  PubMed          Journal:  Signal Transduct Target Ther        ISSN: 2059-3635


  483 in total

1.  SARS-CoV-2 Kappa Variant Shows Pathogenicity in a Syrian Hamster Model.

Authors:  Pragya D Yadav; Sreelekshmy Mohandas; Anita M Shete; Dimpal A Nyayanit; Nivedita Gupta; Deepak Y Patil; Gajanan N Sapkal; Varsha Potdar; Manoj Kadam; Abhimanyu Kumar; Sanjay Kumar; Deepak Suryavanshi; Chandrashekhar S Mote; Priya Abraham; Samiran Panda; Balram Bhargava
Journal:  Vector Borne Zoonotic Dis       Date:  2022-05       Impact factor: 2.133

2.  Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease.

Authors:  Wenhao Dai; Bing Zhang; Xia-Ming Jiang; Haixia Su; Jian Li; Yao Zhao; Xiong Xie; Zhenming Jin; Jingjing Peng; Fengjiang Liu; Chunpu Li; You Li; Fang Bai; Haofeng Wang; Xi Cheng; Xiaobo Cen; Shulei Hu; Xiuna Yang; Jiang Wang; Xiang Liu; Gengfu Xiao; Hualiang Jiang; Zihe Rao; Lei-Ke Zhang; Yechun Xu; Haitao Yang; Hong Liu
Journal:  Science       Date:  2020-04-22       Impact factor: 47.728

3.  The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern.

Authors:  Rana Abdelnabi; Caroline S Foo; Dirk Jochmans; Laura Vangeel; Steven De Jonghe; Patrick Augustijns; Raf Mols; Birgit Weynand; Thanaporn Wattanakul; Richard M Hoglund; Joel Tarning; Charles E Mowbray; Peter Sjö; Fanny Escudié; Ivan Scandale; Eric Chatelain; Johan Neyts
Journal:  Nat Commun       Date:  2022-02-15       Impact factor: 14.919

4.  Targeting omicron and other reported SARS-CoV-2 lineages by potent inhibitors of main protease 3CL Mpro: Molecular simulation analysis.

Authors:  Aamir Saeed; Basharat Ahmad; Sidra Majaz; Faisal Nouroz; Ashfaq Ahmad; Yingqiu Xie
Journal:  J Infect       Date:  2022-02-17       Impact factor: 38.637

5.  Design of SARS-CoV-2 Mpro, PLpro dual-target inhibitors based on deep reinforcement learning and virtual screening.

Authors:  Li-Chuan Zhang; Hui-Lin Zhao; Jin Liu; Lei He; Ri-Lei Yu; Cong-Min Kang
Journal:  Future Med Chem       Date:  2022-02-27       Impact factor: 3.808

6.  Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021.

Authors:  Finlay Campbell; Brett Archer; Henry Laurenson-Schafer; Yuka Jinnai; Franck Konings; Neale Batra; Boris Pavlin; Katelijn Vandemaele; Maria D Van Kerkhove; Thibaut Jombart; Oliver Morgan; Olivier le Polain de Waroux
Journal:  Euro Surveill       Date:  2021-06

7.  Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody.

Authors:  Xiaolong Tian; Cheng Li; Ailing Huang; Shuai Xia; Sicong Lu; Zhengli Shi; Lu Lu; Shibo Jiang; Zhenlin Yang; Yanling Wu; Tianlei Ying
Journal:  Emerg Microbes Infect       Date:  2020-02-17       Impact factor: 7.163

8.  SARS-CoV-2 Membrane Protein: From Genomic Data to Structural New Insights.

Authors:  Catarina Marques-Pereira; Manuel N Pires; Raquel P Gouveia; Nádia N Pereira; Ana B Caniceiro; Nícia Rosário-Ferreira; Irina S Moreira
Journal:  Int J Mol Sci       Date:  2022-03-10       Impact factor: 5.923

9.  Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention.

Authors:  Zunyou Wu; Jennifer M McGoogan
Journal:  JAMA       Date:  2020-04-07       Impact factor: 56.272

10.  Mechanisms of Myocardial Injury in COVID-19.

Authors:  Anda Bularga; Andrew R Chapman; Nicholas L Mills
Journal:  Clin Chem       Date:  2021-08-05       Impact factor: 8.327

View more
  5 in total

Review 1.  SARS-CoV-2 and Emerging Foodborne Pathogens: Intriguing Commonalities and Obvious Differences.

Authors:  Ahmed G Abdelhamid; Julia N Faraone; John P Evans; Shan-Lu Liu; Ahmed E Yousef
Journal:  Pathogens       Date:  2022-07-27

2.  Differences Between Omicron Infections and Fever Outpatients: Comparison of Clinical Manifestations and Initial Routine Hematology Indicators.

Authors:  Xiaojie Bi; Ying Zhang; Juan Pan; Chaochao Chen; Yufen Zheng; Jing Wang; Mengyuan Chen; Kai Zhou; Tao-Hsin Tung; Bo Shen; Donglian Wang
Journal:  Infect Drug Resist       Date:  2022-08-31       Impact factor: 4.177

Review 3.  Omicron variant (B.1.1.529) and its sublineages: What do we know so far amid the emergence of recombinant variants of SARS-CoV-2?

Authors:  Manish Dhawan; AbdulRahman A Saied; Saikat Mitra; Fahad A Alhumaydhi; Talha Bin Emran; Polrat Wilairatana
Journal:  Biomed Pharmacother       Date:  2022-08-15       Impact factor: 7.419

Review 4.  Publication trends of research on COVID-19 and host immune response: A bibliometric analysis.

Authors:  Yun Xia; Ren-Qi Yao; Peng-Yue Zhao; Zheng-Bo Tao; Li-Yu Zheng; Hui-Ting Zhou; Yong-Ming Yao; Xue-Min Song
Journal:  Front Public Health       Date:  2022-08-08

5.  SARS-CoV-2 Monitoring in Wastewater Reveals Novel Variants and Biomarkers of Infection.

Authors:  Jenna McGowan; Monica Borucki; Hicham Omairi; Merina Varghese; Shahnaz Vellani; Sukanya Chakravarty; Shumin Fan; Srestha Chattopadhyay; Mashuk Siddiquee; James B Thissen; Nisha Mulakken; Joseph Moon; Jeffrey Kimbrel; Amit K Tiwari; Roger Travis Taylor; Dae-Wook Kang; Crystal Jaing; Ritu Chakravarti; Saurabh Chattopadhyay
Journal:  Viruses       Date:  2022-09-13       Impact factor: 5.818

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.